Loading...
Market
Which major pharmaceutical company will first partner with Washington University for Alzheimer's research by the end of 2024?
2
Resolution / Starting Odds
Pfizer • 25%
Roche • 25%
Merck • 25%
Other • 25%
Official press releases or news articles
Story
New Technique Models Late-Onset Alzheimer's Using Patient-Derived Neurons, Lamivudine Shows Promise
Aug 1, 2024, 09:08 PM
Researchers at Washington University School of Medicine have developed a new technique to model late-onset Alzheimer's disease using patient-derived neurons. This method involves transforming skin cells into induced pluripotent stem cells and then into neurons, which accurately replicate the disease's features. The study, published in Science Magazine, identifies the role of retrotransposons, or 'jumping genes,' in Alzheimer's disease. This approach allows scientists to study the effects of aging on Alzheimer's without the need for brain biopsies. Additionally, the drug lamivudine has shown to reduce Alzheimer's effects in lab-grown neuron models.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Eli Lilly • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Eli Lilly • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%